ArticleAmerican journal of clinical and experimental immunology2018
Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review.
Article in American journal of clinical and experimental immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Consecutive PRES and diffuse alveolar hemorrhage in a patient with active lupus nephritis and antiphospholipid antibodies: a case report and systematic literature review.BMC nephrology · 2026Pooled it
- Posterior reversible encephalopathy syndrome as a rare presentation of systemic lupus erythematosus: a case report.Annals of medicine and surgery (2012) · 2026Article
- Article
- Fatal PRES and super-refractory status epilepticus after combined heart and kidney transplant: A case report and literature review.JHLT open · 2024Review
- The challenging clinical dilemma of posterior reversible encephalopathy syndrome in systemic lupus erythematosus.Zeitschrift fur Rheumatologie · 2024Article
- Post reversible encephalopathy syndrome attributed to mycophenolate mofetil used in the treatment of SLE: A case report and review of literature.The Journal of international medical research · 2024Review
- Systemic lupus erythematosus complicated with reversible posterior encephalopathy syndrome: a case report.The Journal of international medical research · 2021Article
- Posterior reversible encephalopathy syndrome presenting as refractory status epilepticus in a patient taking Mycophenolate mofetil for IgA nephropathy: A case report.Annals of medicine and surgery (2012) · 2021Article
- A Case of Antibiotic-Induced Posterior Reversible Encephalopathy Syndrome.Hospital pharmacy · 2020Article
- Article
- Neurological Complications in Patients with Systemic Lupus Erythematosus.Current neurology and neuroscience reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a rare clinical entity associated with systemic lupus erythematosus which characterized by seizure, headache, and altered mental status. The pathophysiology involves subcortical vasogenic edema secondary to hypertension and endothelial damage. PRES is reversible with withdrawal of the offending agent, strict blood pressure control, and treating the underlying disease. We report present here a patient with lupus nephritis who developed PRES following mycophenolate administration.
Indexed as
Identifiers
29531864PMC5840284W2987172610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.